Help Patients Overcome Hurdles With GLP-1 Agonists
February 2024
Rxs are rolling in for GLP-1 agonists...liraglutide (Victoza, etc), semaglutide (Ozempic, etc), dulaglutide (Trulicity), etc.
It’s partly because these injectable meds are a first-line option for type 2 diabetes in patients who also have certain medical conditions...such as heart or kidney disease.
Plus injectable semaglutide (Wegovy) or tirzepatide (Zepbound) seem to be the most effective Rxs for managing overweight or obesity.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote